08:10 AM EDT, 10/27/2026 (MT Newswires) -- Abionyx Pharma (ABNX.PA) entered into a strategic manufacturing partnership with Axplora, marking the completion of the structuring of the CER-001 bioproduction chain. Axplora will apply its specialist purification expertise to recombinant human apoA-I, the key biological component of CER-001, according to a Tuesday release. Work will be conducted at Axplora's Pompey site in France. The biotechnology company's CER-001 is a biopharmaceutical comprising recombinant human apoA-I and phospholipids that forms a biomimetic high-density lipoprotein particle designed to enhance the body's immune response by eliminating endotoxins. It is being developed for LCAT deficiency and sepsis.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.